SOPHIA ANTIPOLIS, FRANCE--(Marketwire - September 19, 2011) - www.nicox.com
NicOx S.A. (NYSE Euronext Paris: COX) today announced that new
results obtained with NCX 6560 were presented at the European Muscle
in Berlin, the annual meeting of the European Society for Muscle
NCX 6560 is an innovative nitric oxide (NO)-donating atorvastatin
previously completed a successful phase 1b study, including a
evaluation of its cholesterol-lowering effect in subjects with high LDL
Density Lipoprotein)-cholesterol. NicOx is currently evaluating
cardiovascular indications for NCX 6560 where NO donation may bring the
Statins are commonly used for lowering abnormally raised cholesterol
associated with side effects, including skeletal muscle adverse events
pain and weakness. Observational studies estimate that 10 to 15% of statin
experience muscle-related adverse events, known as statin-induced
which may lead them to discontinue the treatment. This is a significant
for patients at high risk of cardiovascular events who need to
efficacious lipid-lowering therapy.
The study presented at the European Muscle Conference assessed the
atorvastatin, a reference statin, and NCX 6560 on muscle function
preclinical model. In this model, atorvastatin affected muscle
induced muscle fiber atrophy. NCX 6560, at a dose producing the same
level of atorvastatin, did not show these adverse effects, which suggests
NO may have a beneficial effect in preventing statin-induced
abstract has been published in the Journal of Muscle Research and
 Abd TT, Jacobson TA, Statin-induced myopathy: a review and update.
Opin. Drug Saf. 2011, 10(3):373-87.
 D'Antona G, Mascarto A, Monopoli A, Miglietta D, Ongini E,
Nitric oxide preserves from atorvastatin-induced skeletal muscle damage in
J Muscle Res Cell Motil. 2011, in press.
NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is a pharmaceutical company
on the research, development and future commercialization of drug
NicOx is applying its proprietary nitric oxide-donating R&D platform to
an internal portfolio of New Molecular Entities (NMEs) for the
treatment of inflammatory, cardio-metabolic and ophthalmological diseases.
The Company's pipeline includes several nitric oxide-donating NMEs, which
development internally and with partners, who include Merck (known
outside the United States and Canada), Bausch + Lomb, and Ferrer.
NicOx S.A. is headquartered in France and is listed on Euronext
(Compartment B: Mid Caps).
This press release contains certain forward-looking statements.
Company believes its expectations are based on reasonable assumptions,
forward-looking statements are subject to numerous risks and
which could cause actual results to differ materially from those
the forward-looking statements.
Risks factors which are likely to have a material effect on NicOx's
presented in the 4th chapter of the « Document de
référence, rapport financier
annuel et rapport de gestion 2010 » filed with the French
Autorité des Marchés
Financiers (AMF) on February 25, 2011 and available on NicOx's
(www.nicox.com) and on the AMF's website (www.amf-france.org).
NicOx presents new preclinical data for NCX 6560:
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.